Optimize: Healthy Aging

The most accessible longevity lever. Dose-response all-cause mortality: 7,000 vs 2,000 steps/day ~47% lower death, benefit detectable from ~2,600. Observational but large, consistent, and biologically coherent. Empower-first anchor #1.

Aerobic base training raises cardiorespiratory fitness, among the strongest mortality predictors known (least-fit ~5x the death rate of fittest). Overlaps vo2max-training and hiit as one aerobic-fitness pillar.

Directly-measured VO2max: each 1-MET tracks 11-16% lower mortality, both sexes, no ceiling. Same aerobic pillar as zone-2; training is the lever, the VO2max number itself is a marker (see markers).

Empower-first pillar: ~21% lower mortality alone, ~40% with added cardio; also the primary defense against sarcopenia, falls, and bone loss that drive late-life decline. Mortality evidence is observational (moderate), the muscle/independence case is strong.

Best-evidenced dietary pattern for healthspan: umbrella-strong for lower death, heart disease, diabetes, neurodegeneration; ~56% lower odds of frailty. Empower-first diet anchor.

Sleep is a foundational pillar. Steadiest sleepers had 20-48% lower death risk, and regularity predicted survival better than duration. The specific mortality evidence is preliminary/observational; the pillar itself is core. Pair with the sleep-duration completeness item.

The minimum effective dose of the strength pillar: 30-60 min/week tracks 10-20% lower death, benefit flattens past ~1 hr/week. Same evidence base as resistance-training; useful as the on-ramp, not a separate lever.

Most fiber subtypes track lower death (insoluble strongest, HR ~0.77); each 10 g/day ~10% lower colorectal cancer. Component of the whole-food/Mediterranean pattern; solid observational.

Two directions in one topic: heaviest ultra-processed eaters ~25% higher death (reduce-lever), closer Mediterranean-pattern eating lower death/CVD/cancer/dementia. Overlaps mediterranean-diet; surface as 'eat mostly whole foods, less ultra-processed.'

Moderate coffee ~16% lower death and lower diabetes risk. Robust, replicated observational U-shape; a genuine everyday lever, not just a stimulant.

Reduce-lever: more total sitting and long unbroken bouts track higher death (all-cause HR ~1.24); ~60-75 min/day of activity offsets 8+ hr sitting. Surface as 'sit less, break it up,' complements the exercise pillars.

Reduce-lever. Corrected for abstainer bias, low-volume drinking shows no mortality benefit; dose-response cancer harm (breast cancer up ~15% at 3-6 drinks/week; ~741,300 alcohol-attributable cancers in 2020). Surface as 'less alcohol,' never as a longevity practice.

~17% lower risk of death and of heart attack/stroke with stronger purpose; ikigai HR 0.85 men / 0.93 women in 73,272 adults. Confounded (health drives purpose too), but the association is large and replicated. Psychosocial pillar.

UNDERSTATED in the input (only a single 'emerging' volunteering claim). The wider literature (Holt-Lunstad meta-analysis) puts social connection near the strength of smoking-cessation for survival. Curate as a proven psychosocial pillar; see completeness for the stronger primary source.

Volunteers ~24% less likely to die over follow-up (47% before health adjustment, so heavily confounded); benefit concentrated in other-oriented motivation. A specific expression of the social-connection/purpose pillars, not an independent lever.

Each step up in neighborhood greenery ~4% lower death. Modest effect, confounded by neighborhood wealth and walkability; genuine but small. Frame as an access-aware, low-cost adjunct.

Part of the aerobic-fitness pillar. Generation 100 found no SIGNIFICANT all-cause mortality reduction in adults 70-77 over 5 years (the trial was underpowered for deaths), but fitness gains were real. Benefit runs through CRF; not a standalone mortality lever above general aerobic training.

Frequent sauna tracks ~half the cardiovascular deaths (12% vs 22%) in the Finnish cohort. Single-population observational, plausibly confounded by who saunas frequently; reasonable but not established. Access-limited.

Most daytime light exposure ~17-34% lower death over 8 years. Preliminary and confounded (healthy people get outdoors more), but the circadian mechanism is real and the lever is free. Pairs with sleep-regularity.

Drug. Strong: ~12% lower all-cause death in type 2 diabetes (CVOT meta-evidence). Empower-first LAST-RESORT framing, education-level: a genuine mortality lever for people with diabetes/obesity, not a longevity drug for metabolically healthy people.

Hearing-aid use tracks ~24% lower mortality in people with hearing loss (confounded). The real weight: untreated hearing loss is a leading modifiable dementia risk factor (Lancet Commission). Correcting hearing loss is a legitimate cognition/aging lever; the mortality figure is soft.

Genuinely two-directional: sun avoidance tracked 0.6-2.1 fewer life-years (confounded), but burning/intermittent sun and tanning beds raise melanoma (strong harm; beds +87% if started before 35), and sunscreen halved melanoma in the one RCT. Do NOT frame sun as a longevity lever; frame as sensible daylight without burning.

Off primary goal: the claim is breast-cancer quality-of-life and fatigue (QoL SMD 0.22, fatigue SMD -0.48), i.e. cancer supportive care, not a healthy-aging mortality lever. Keep as a mind-body/recovery adjunct.

Turkey-tail PSK as a chemotherapy adjunct improved gastric-cancer survival (established in Japan); reishi adjunct improved tumor response/QoL (emerging). This is oncology adjunct care, not a general anti-aging lever. Education-level; watch for industry framing on both the benefit and the skeptic sides.

Guideline-recommended to prevent chemo/radiotherapy mouth sores (oral mucositis). Narrow supportive-care indication mistagged onto healthy-aging via the cancer group; not a longevity lever.

Mostly null: across 84 trials in 739,803 adults supplements did little to prevent cancer/CVD/death (USPSTF); SU.VI.MAX null overall; one weak PHS II signal (~8% total cancer in older men) and an Iowa observational HIGHER-mortality link. Not a lever; a modest insurance-policy at best. Do not surface as 'start here.'

Strong NO-EFFECT in replete adults: VITAL (25,871) no fewer cancers on 2000 IU; DO-HEALTH no gains in BP, fractures, strength, infection, or memory. Correcting genuine deficiency is a different question; supplementing replete people is not a longevity lever. Direction-aware: a strong null, never a 'start here.'

FRONTIER, education-level. Mouse lifespan only (ITP: ~9-14% late-life, ~23-26% at higher dose). No human longevity or healthspan RCT exists. Compelling animal signal, real immune/mTOR mechanism, but must not read as a strong human lever. See overGradedTiers.

FRONTIER. Clearing senescent cells delayed aging phenotypes and extended median lifespan in aged MICE; fisetin similar. No human trial has shown senolytics extend life or prevent disease. Education-level; the per-claim tiers are already honestly preliminary.

FRONTIER. Fisetin was the strongest senolytic flavonoid extending lifespan in aged mice. Human longevity data absent; sold well ahead of the evidence. Same frontier bucket as senolytics.

Extends lifespan in yeast/flies/worms/mice; higher dietary intake tracks lower mortality (HR ~0.76/SD) in a single confounded cohort. Autophagy mechanism is interesting but human evidence is one observational signal plus model organisms. See overGradedTiers.

FRONTIER. ~10-12% median lifespan gain in middle-aged mice; in people blood taurine falls with age and tracks worse cardiometabolic markers (correlation only, reverse causation likely). No human outcome trial. Education-level.

Human data largely null: no lifespan gain in mice on a normal diet, and dietary resveratrol showed NO link to death/CVD/cancer in older adults. The famous benefit was confined to mice on a high-calorie diet. Lean toward a null/hype topic, not a lever.

FRONTIER. Extended male-mouse median lifespan ~22% (ITP), much less in females; dose-dependent. A glucose-lowering drug with no human longevity trial. Education-level.

FRONTIER for longevity specifically: canagliflozin extended male-mouse lifespan ~14%, none in females; no completed human trial shows these drugs extend healthy lifespan. (Strong cardiorenal drug in its own diseases, but that is a different goal.) Education-level.

FRONTIER. TAME (metformin vs aging) has not reported; the observational 'users outlived non-diabetics' result is confounded and partly contradicted by exercise-blunting data. No causal human longevity evidence. Education-level.

WATCH over-grade. No human trial has shown NAD+ precursors extend healthspan or lifespan; striking results are model-organism or surrogate-marker only. Heavily marketed. Correctly a null/unproven topic here, not a benefit lever; keep it that way.

No human study shows urolithin A slows aging or extends life; mitophagy mechanism plus muscle-endurance surrogates only. Emerging/education, not a lever.

GlyNAC raised glutathione and improved aging markers, but the evidence is a 24-person, mostly single-group, single-team body of work. Interesting redox mechanism; nowhere near a lever. Education-level, flag replication limit.

FRONTIER. The 'telomeres lengthened >20%' result was 35 older adults with NO control group; surrogate endpoint, uncontrolled. Expensive, over-marketed for anti-aging. Education-level, heavy skepticism.

FRONTIER. No completed human trial shows young-donor plasma or plasma exchange slows aging. Sold by clinics well ahead of evidence. Education-level, strong skepticism.

CAUTION. Marketed for anti-aging but the longevity evidence points the OTHER way: lower IGF-1 predicted longer survival in nonagenarians, and dampened IGF-1 signaling is overrepresented in centenarians. Surface as a caution against the anti-aging pitch, not a lever.

All-cause and heart-disease death lower in heaviest drinkers (women HR 0.77/0.69), but no clear cancer-prevention signal across trials. Confounded observational; a reasonable everyday beverage, modest evidence.

Most fermented soy tracked ~10% lower mortality while total soy showed no link. Single-population, confounded; interesting microbiome angle but preliminary.

Hot-button and confounded: French cohort ~25% lower cancer in highest organic eaters, larger UK cohort null overall. Organic eaters differ in wealth, diet quality, and activity. Present both cohorts symmetrically; not a lever.